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spasticity associated with a variable combination of neu-
rologic and extra-neurologic signs and symptoms. Among 
ability is a frequent subtype, often inherited as a recessive 
trait (ARHSP-TCC). Within this heterogeneous subgroup, 
Abstract     Complicated hereditary spastic paraplegias       associated with early-onset forms of ARHSP with and 
(HSP) are a heterogeneous group of HSP characterized by       without TCC, CYP2U1/SPG56, DDHD2/SPG54 and 
GBA2/SPG46, in a large population of selected compli-
cated HSP patients by using a combined approach of 
tra- them, HSP with thin corpus callosum and intellectual dis- ditional-based and amplicon-based high-throughput 
pooled-sequencing. Three families with mutations were 
identiﬁed, one for each of the genes analyzed. Novel 
SPG11 and SPG15 represent the most frequent subtypes.       homozygous mutations were identiﬁed in CYP2U1 
We analyzed the mutation frequency of three genes       (c.1A[C/p.Met1?)       and       in       GBA2       (c.2048G[C/ 
p.Gly683Arg), while the homozygous mutation found in 
DDHD2 (c.1978G[C/p.Asp660His) had been previously 
reported in a compound heterozygous state. The pheno-
types associated with the CYP2U1 and DDHD2 mutations 
overlap the SPG56 and the SPG54 subtypes, respectively, 
A. Citterio and A. Arnoldi contributed equally to this work. 
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spectrum of clinical entities associated with GBA2 muta-
tions. Overall, each of three genes analyzed shows a low 
mutation frequency in a general population of complicated 
HSP (\1 % for either CYP2U1 or DDHD2 and approxi-
mately 2 % for GBA2). These ﬁndings underline once 
again the genetic heterogeneity of ARHSP-TCC and the 
clinical overlap between complicated HSP and the reces-
sive ataxia syndromes. 
Spastic paraparesis _ CYP2U1 _ DDHD2 _ GBA2 
Introduction 
Hereditary spastic paraplegias (HSP) constitute a group of 
weakness of the lower limbs due to retrograde axonal 
degeneration of the corticospinal tracts and posterior col- 
Complicated forms of HSP are characterized by the 
presence of variable combinations of neurologic features 
such as ataxia, peripheral neuropathy, intellectual disability, 
epilepsy or extraneurologic signs in addition to spasticity 
[4]. HSP with thin corpus callosum (HSP-TCC) and intel-
lectual disability is a frequent subtype of complicated HSP, 
often inherited as an autosomal recessive trait (ARHSP-
TCC) [5, 6]. It is clinically characterized by slowly pro-
gressive spastic paraparesis and mental deterioration mainly 
beginning before the second decade of life. A wide genetic 
heterogeneity characterizes this subgroup of complicated 
HSP with several genes identiﬁed such as SPG21, SPG11, 
ZFYVE26/SPG15, FA2H, AP4S1, AP4M1, AP4B1 [6], and 
more recently CYP2U1 [7], DDHD2 [8], TECPR2 [9] and 
GBA2 [10, 11]. The two genes most frequently mutated in 
these forms are SPG11 and ZFYVE26/SPG15, accounting 
for 20 % and 3 % of the cases, respectively, with almost 
indistinguishable clinical phenotypes [12–14]. With regard 
TECPR2 and GBA2, both mutation frequencies and the full 
range of associated phenotypes still need to be deﬁned. We 
tried to ﬁll this gap by screening for mutations a cohort of 
paraparesis for CYP2U1 and DDHD2 mutations. Forty-six 
of them were also screened for GBA2 mutations. Herein, we 
tiﬁed in each of the three genes tested and the clinical-
genetic and diagnostic implications of these ﬁndings. 
with few differences. By contrast, the GBA2 mutated Patients and methods 
patients show phenotypes combining typical features of 
both the SPG46 subtype and the recessive ataxia form, with Patients 
marked intrafamilial variability thereby expanding the 
We studied the index subjects of 150 HSP families (140 of 
Italian origin and 10 from North Africa) with slowly pro-
gressive complicated spastic paraparesis and intellectual 
disability. Ninety patients were sporadic while 60 were 
from recessive families. A variable combination of axonal 
neuropathy and signs of lower motor neuron degeneration 
were present in almost all of them. The majority of the 
patients (n = 125) showed TCC either isolated or with a 
variable pattern of white matter abnormalities (WMA), 
Keywords Amplicon-based targeted resequencing _ cerebellar and cerebral atrophy at the MRI analysis, by 
contrast, 25 patients had a normal MRI. Symptoms onset 
was between 0 and 18 years of age. Clinical data of the 
patients were obtained by clinical evaluation by the refer-
ring neurologist, based on the Harding criteria [15] for the 
deﬁnition of the clinical status and, thus, excluding any 
possible alternative cause of spastic paraplegia. The Intel- 
clinically and genetically heterogeneous neurodegenerative       ligence quotient (IQ) evaluated through the Wechsler 
diseases characterized by progressive spasticity and       Intelligence Scales for Children or for Adult along with a 
detailed neuropsychological evaluation (Wechsler Memory 
Scale), was available for 98 % of the cases. All families 
umns [1–3]. had been previously screened for mutations in SPG7, 
SPG11, SPG15, SPG21 and SPG35 with negative results. 
ALS2, SIGMA1R and ERLIN2 mutations were also exclu-
ded in all patients with normal MRI. SPG4 and SPG3A 
mutations were also excluded in all patients with appar-
ently sporadic occurrence of the disease. 
Genetic analysis 
We obtained blood samples and clinical data from affected 
and unaffected subjects of the pedigree under a protocol of 
informed consent approved by the Ethics Committee of the 
E. Medea Scientiﬁc Institute. DNA was puriﬁed by using a 
standard high-salt puriﬁcation method. 
Mutation analysis of the coding exons of CYP2U1, 
DDHD2, GBA2 genes was performed by using a combined 
approach of Sanger sequencing and targeted resequencing. 
In detail, CYP2U1 and DDHD2 coding exons were ﬁrst 
directly sequenced in 104 patients by the Sanger method. 
to the most recently identiﬁed genes CYP2U1, DDHD2, Sequences were prepared with a Big Dye Terminator 
sequencing Kit (version 3.1 Applied Biosystem, Foster 
City, USA) and run on an ABI 3130xL or ABI3500xLDx 
sequencing apparatus (Applied Biosystem). Additional 46 
150 patients with recessive or sporadic complicated spastic patients were screened for mutations in the CYP2U1, 
DDHD2 and GBA2 genes in a pilot experiment of ampli-
con-based high-throughput pooled-sequencing performed 
report the result of the screening with the mutations iden- by using a Fluidigm Access Array System (Fluidigm 
Corporation, San Francisco, CA, USA) for amplicon gen-
eration followed by the Nextera technology (Illumina, San 
 
Diego, CA, USA) for targeted resequencing, using a MiSeq 
apparatus (Illumina). Sets of primers used to amplify the 
genomic fragments containing all coding exons of the three 
mentary ﬁle. Technical details for targeted NGS experi-
ments are provided as an Online Resource. Brieﬂy, 93 % of 
the NGS fragments for each gene had coverage of at least 
399 reads and passed quality control. The remaining 7 % 
that did not pass the quality control were re-sequenced by 
Sanger sequencing. Variants detected were validated by 
Sanger sequencing. 
All variants were checked against a panel of 600 Italian 
controls and against the dbSNP and 1,000 genome data-
base. Mutation nomenclature is according to the recom-
mendations of the Human Genome Variation Society and 
refers to the published CYP2U1, DDHD2 and GBA2 cDNA 
Missense changes were analysed for possible pathogenic 
effects on protein function by using different prediction 
software (MutPred, SIFT, SNAP, PhD-SNP, SNPs&GO, 
Panther and Provean). 
Results 
Genetic ﬁndings 
One hundred and ﬁfty patients were screened for CYP2U1 
and DDHD2 genes; 46 of these patients were additionally 
screened for GBA2 mutations. This work led to the iden-
tiﬁcation of three families carrying a mutation (Table 1), 
affecting the ATG codon (c.1A[C, p.Met1?) was found in 
patient P574 (Fig. 1). As a consequence, a putative trun-
cated protein missing the ﬁrst 209 amino acid residues is 
predicted to be synthesized starting from the next in-frame 
inherited by both parents. 
The index patient of family P1242 was found to carry a 
homozygous base change in exon 16 of DDHD2 gene, 
c.1978G[C, p.Asp660His (Fig. 1) previously described in 
a compound heterozygous state in another family [8]. This 
affected sister (Fig. 1). 
A pilot experiment of amplicon-based high-throughput 
pooled-sequencing led to the identiﬁcation of a single 
c.2048G[C, p.Gly683Arg, in the proband of family P922. 
The sequence change inherited from the parents, segre-
gated in the two proband’s brothers with subclinical signs 
conserved and falls within the glucosylceramidase domain 
of the GBA2 protein, just upstream from the transmem-
brane domain (residues 689–708) [16]. This change is 
genes through the Fluidigm technology are in a supple- predicted to be either deleterious/damaging or disease 
found by the software used (see ‘‘Methods’’). 
The missense changes here identiﬁed in the three genes 
were checked against a panel of 600 controls, the dbSNP 
and the 1,000 genome database. 
Clinical ﬁndings 
Clinical and radiological features of the three families with 
mutations are summarised in Table 1 while detailed clini-
cal description is provided as an Online Resource. Overall, 
the CYP2U1-mutated patient presents an early-onset pure/ 
mildly complicated form of the diseases, with subclinical 
sequences (Acc. NM_183075.2, NM_015214.2 and signs of neuropathy, without sensory deﬁcits or intellectual 
NM_020944.2, respectively) with nucleotide ?1 corre- disability with normal MRI. The DDHD2 mutated patients 
sponding to the A of the ATG translation initiation codon. display clinical and neuroradiological (Fig. 2) features 
partly overlapping the SPG11 subtype with a more severe 
phenotype and an earlier onset. The GBA2 family includes 
a pair of dizygotic twins and a third brother, overall dis-
playing a phenotype characterized by spasticity, mild cer-
ebellar signs and moderate eyelid ptosis with a different 
degree of severity in the proband (severe spasticity, difﬁ-
culty in walking and frequent falls) with respect to the two 
brothers (evidence of clinical signs only at neurological 
examination). 
Discussion 
CYP2U1, DDHD2 and GBA2 genes are associated with 
one for each of three genes. A mutation in CYP2U1 early-onset complicated forms of HSP with a variable 
degree of mental impairment and TCC at the MRI [7, 8, 
10]. GBA2 was also found mutated in a recessive form of 
ataxia with neuropathy and spasticity [11]. 
Mental impairment and TCC at the MRI are more 
ATG located 628 bases downstream. This mutation was consistently present in the DDHD2-related subtype 
(SPG54) with respect to the CYP2U1 one, SPG56 (previ-
ously referred as SPG49) [7, 8]. 
The SPG56 subtype shows indeed a wide range of 
variability with a mix of complicated and pure forms of 
disease with early-onset (from birth to age 8) [7]. SPG56 
mutation, inherited by both parents, segregated also in the complicated patients frequently show spasticity at the 
upper limbs, rare dystonic postures, cognitive alteration 
and subclinical neuropathy mainly at the lower limbs. At 
the neuroradiology level, TCC and WMA may be present 
homozygous mutation in exon 13 of the GBA2 gene, [7]. Analogously, in SPG54, the ﬁrst symptoms of spas- 
ticity appear at age 2 frequently preceded by a psycho-
motor delay that develops into intellectual disability [8]. 
Signs of spasticity at the upper limbs, dysarthria and dys- 
of the disease. The Gly683 mutant residue is evolutionary phagia are frequently observed. Brain MRI reveals a 
 
Table 1 Clinical Features of the patients carrying the DDHD2, CYP2U1 or GBA2 mutations 
Patient P1242 II-1 P1242 II-2 P574 P922 II-1 P922 II-2 P922 II-3 
Mutation DDHD2 c.1978G[C, p.Asp660His CYP2U1 c.1A[C, 
p.Met1? 
GBA2 c.2048G[C, p.Gly683Arg 
Consanguinity No Yes Yes 
Age at onset (y)/ 
symptoms at 
onset 
3 months/distal 
movements, 
myoclonus like 
18 months/ 
developmental 
delay 
18 months/ 
developmental 
delay 
10/gait 
impairment 
No symptoms No symptoms 
Disease duration/ 
years 
15 21 3 14 / / 
Disability score 
(n/7) 
4 6 5 3 1 1 
Severe Severe Severe Moderate No LL spasticity 
LL reﬂexes 
Moderate-severe 
Brisk Brisk Ankle clonus Brisk/Polikinetic 
ankle clonus 
Brisk, ankle 
clonus 
Brisk, ankle 
clonus 
Brisk, ankle 
clonus 
Mild Mild 
Mild distal 
LL weakness 
LL amyotrophy 
Babinski sign 
Mild distal 
? 
Severe 
Moderate distal 
? 
Moderate 
– 
? ? on the right 
side 
– 
– 
– 
– 
– 
– 
– 
Slightly Brisk 
UL spasticity 
UL reﬂexes 
UL weakness 
Mild 
Brisk 
Mild 
Mild-moderate 
Brisk 
Mild-moderate Slight clumsiness of 
distal ﬁne 
movements 
Moderate 
Brisk 
– 
– 
Brisk 
– 
– 
Brisk 
– 
UL amyotrophy 
Dysarthria 
Superﬁcial 
sensory 
abnormalities 
Mild distal 
? 
– 
Mild distal 
? 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
Deep sensory 
abnormalities 
Not evaluable Not evaluable Not evaluable – – – 
Pes cavus/ 
scoliosis 
-/? -/? Kyphosis Flatfoot/- -/- Flatfoot/- 
Urinary 
symptoms 
– Sphinteric control 
never acquired 
– Urinary 
incontinence 
– – 
Mental status Mental retardation Mental retardation Normal, except for 
expressive 
language delay 
Normal Normal Normal 
Ataxia/other 
cerebellar signs 
? ? – Mild dysmetria Mild dysmetria Mild dysmetria 
Eye movement 
abnormalities 
Absent Absent – Eyelid ptosis Left eyelid 
ptosis 
Eyelid ptosis 
Normal Normal Visual acuity 
Cerebral MRI TCC PWMH 
(periventricular 
white-matter 
hyperintensities) 
Global WM 
reduction 
TCC PWMH Mild 
cerebellar atrophy-
mild brainstem 
atrophy 
Normal 
Normal 
Mildly reduced 
Normal 
Normal 
NA 
Normal 
NA 
ENMG Normal Mild reduction of 
motor nerve 
velocity 
Slight chronic 
neurogenic signs at 
needle 
electromyography, 
normal conduction 
studies 
Normal NA NA 
 
consistent pattern of abnormalities including TCC and a 
variable degree of periventricular hyperintensities [8]. 
The families carrying mutations identiﬁed in this screening 
P574 (CYP2U1) and P1242 (DDHD2) show features largely 
overlapping with the described SPG56 and SPG54 pheno-
types, respectively. Nevertheless, in the family with the 
DDHD2 mutation, the presence of behavioural abnormalities 
and attention deﬁcits in one of the affected sibs was not 
reported so far. Short stature, which was reported as one of the 
key feature of DDHD2-related HSP [17], is not observed in 
this family.Based on the clinical featuresobserved, the SPG54 
subtype, although overlapping with SPG11, shows an overall 
Table 1 continued 
Patient P1242 II-1 P1242 II-2 P574 P922 II-1 P922 II-2 P922 II-3 
Other Behavioural 
disturbances- 
Cognitive decline – – Positive 
Hoffman sign 
Positive 
Hoffman sign 
LL lower limbs, UL upper limbs, ENMG elechtroneuromyography, NA Not Available, TCC Thin corpus callosum 
? present, - absent 
Disability assessed on a 7 point scale [12]: 1, minimal disability (slight stiffness of the legs); 2, mild disability (unable to run, but full autonomy); 
3, moderate disability when walking (reduced perimeter, frequent falls); 4, severe disability (unilateral support required to walk); 5, bilateral 
support required to walk; 6, wheelchair bound; 7, bedridden. Table data refer to the last clinical evaluation 
Fig. 1 The Pedigrees of 
familial cases carrying 
CYP2U1, DDHD2 and GBA2 
mutations. Diamond symbols 
are for anonymity reasons; 
black and white symbols 
indicate affected and healthy 
subjects, respectively. Arrows 
indicate the probands. 
Electropherograms of the 
mutations identiﬁed in the 
study. The mutant nucleotides 
are boxed. Partial alignment of 
the amino acid sequences 
encompassing the protein 
regions carrying the mutant 
residues is shown below 
 
more severe clinical presentation and an earlier age of 
symptoms onset. The DDHD2 homozygous mutation here 
identiﬁed c.1978G[C (p.Asp660His) was already reported 
in a compound heterozygous state in another family [8].The 
mutation falls within the DDHD domain of the DDHD- 
mammalian intracellular phospholipase A1 (iPLA1) family. 
Members of this family exhibit enzymatic activity and 
hydrolyse the acyl-group of phospholipids in the sn-1 position 
and share a conserved lipase motif (GxSxG) and a DDHD 
domain. This multifunctional domain along with the sterile-
alpha-motif (SAM) is essential for the phospholipase activity 
of the DDHD2 protein [18]. It is possible that DDHD2 plays a 
role by facilitating membrane and vesicle fusion through 
phospholipid hydrolysis. Therefore, the pathogenicity of the 
p.Asp660His mutation affecting a highly conserved residue in 
the DDHD domain likely relies on its effect on the phospho-
lipid hydrolysis activity and, therefore, on membrane fusion 
and/or vesicle trafﬁcking as previously suggested [8, 17]. 
The phenotype of the patient with the CYP2U1 mutation 
overlaps the reported SPG56 phenotype. The patient indeed 
shows a mildly complicated form of the diseases, with only 
subclinical signs of neuropathy at the lower limbs and 
slight involvement of the upper limbs without sensory 
deﬁcits. From the cognitive point of view, he shows only 
an expressive language delay. Based on disease presenta-
tion (see the Online resource) and on the Egyptian origin of 
the consanguineous family, the patient was ﬁrst diagnosed 
domain-containing 2 (DDHD2) protein which belongs to the as a possible Infantile Ascending Spastic Paraparesis 
(IAHSP) or a Juvenile Primary Lateral Sclerosis (JPLS). 
Although at present, genetic ﬁndings along with disease 
evolution indicate a classical form of spastic paraparesis, 
the identiﬁcation of a CYP2U1 mutation in P574 suggests 
the opportunity to perform the CYP2U1 genetic screening 
in very young patients with early-onset pure/mildly com-
plicated HSP, with a suspect of IAHSP/JPLS who had 
tested negative for ALS2, SPG3A and SPG4 mutations. 
This can, thus, facilitate the mutation search in such cases, 
even at the time of disease presentation, without waiting 
for disease evolution. 
The mutation identiﬁed in CYP2U1 is a novel mutation 
disrupting the initiation codon of the protein c.1A[C, 
p.Met1? Assuming that a putative truncated protein could 
still be expressed by the mutant cells, this would lack the 
ﬁrst 209 of the 544 amino acid residues of the wild type 
protein. Therefore, the mutation eliminates about half of 
Fig. 2 MRI of the patient 
carrying the DDHD2 mutation. 
Sagittal T1-weighted (a), 
coronal T2-weighted (b) and 
axial T2-weighted (c, d) and 
FLAIR (e) sections. A markedly 
thin corpus callosum is evident 
on sagittal section (arrow). The 
overall volume of the white 
matter is reduced. T2-weighted 
and FLAIR images show a 
subtle hyper-intense signal 
bilaterally in peritrigonal white 
matter and centrum semiovale 
(arrowheads) 
 
the highly conserved cytochrome P450 functional domain, 
thus leading to a likely loss of protein function. CYP2U1 
hydroxylation of arachidonic acid and related long-chain 
fatty acids, which are mediators of signalling pathways and 
may affect signalling of hormones and neurotransmitters 
tion (P922) show variable phenotype severity ranging from 
severe spasticity with impaired gait in the proband to slight 
unrecognized impairment in his two brothers. The clinical 
picture is mainly overlapping the SPG46 subtype of para-
paresis (pyramidal tract involvement at the onset and pre- 
related recessive ataxia picture. 
Indeed SPG46 and the recessive form of cerebellar 
mutations in GBA2 gene, are quite overlapping and show 
differences in the initial disease presentation. Gait abnor-
malities due to the insidious appearance of stiffness and 
symptoms in the majority of the SPG46 patients described 
so far [10, 19]. With disease progression cerebellar ataxia, 
disability with cerebral, cerebellar and corpus callosum 
atrophy at the MRI are observed [10]. By contrast, pro-
gressive cerebellar ataxia associated with cerebellar dys-
arthria characterizes the initial clinical presentation of all 
[11]. A pyramidal syndrome associated with axonal sen-
sory and sensory-motor neuropathy is then developed by all 
patients [11]. 
Differently from SPG46, none of the patients from the 
P922 family shows signs of cataract or hypogonadism and, 
differently from both the SPG46 and the GBA2-related 
recessive ataxia picture, none of them had evidence of 
peripheral neuropathy, at least at this early stage of the 
disease. Similarly to the already described cases of reces-
sive ataxia, the MRI of P922 proband is normal. 
glucose and ceramide as well as the reverse reaction con-
sisting in the transfer of glucose to different lipid substrates 
[20, 21]. The location of the missense variant, the high 
the family all together point toward a functional relevance 
of the p.Gly683Arg missense change to the pathogenesis. 
On a different level, GBA2 enzyme activity was recently 
biochemically redeﬁned along with its pharmacological 
control by imino-sugars, [22]; therefore, GBA2 mutation 
ﬁndings are instrumental to the characterization of the 
encodes a P450 hydroxylase catalysing the in vitro pathophysiological role of the enzyme in view of a putative 
pharmacological treatment of this form of disease. 
In conclusion, this is the ﬁrst large study conﬁrming the 
phenotypes associated with mutations in either CYP2U1 or 
[7].                                                                                                 DDHD2 genes while identifying a novel intermediate 
Affected members of the family with the GBA2 muta-       GBA2-related phenotype overlapping the two clinical 
entities, SPG46 and the recessive ataxia so far described. 
The intermediate phenotype presented by this patient is in 
line with the wide clinical overlap among complicated HSP 
with cerebellar component, the spastic ataxias and some 
recessive ataxia syndromes. 
dominance of the pyramidal signs in the disease course)            However, the common genetic background of the 
with few clinical aspects reminding one of the GBA2-       SPG46 subtype and the GBA2-related recessive ataxia 
syndrome [11] provides an objective explanation to the 
overlap observed in these two clinical entities. Variable 
ataxia with neuropathy and spasticity, both associated with accumulation of glucosylceramides in the endoplasmic 
reticulum of neuronal cells as one of the postulated con-
sequences of GBA2 loss of function, thus leading to a 
change in calcium homeostasis and neuronal degeneration 
weakness in the lower extremities are the presenting [11], may reasonably account for the clinical heterogeneity 
and overlap observed between the two syndromes. 
The results of the screening indicate also that SPG56, 
neuropathy, cataract and mild to moderate intellectual SPG54 and SPG46 subtypes of paraparesis are not com- 
monly represented in a general population of patients with 
complicated HSP, variable degree of mental impairment 
and a heterogeneous pattern of brain MRI abnormalities. 
Indeed the mutation frequency observed is less than 1 % 
GBA2-related recessive ataxia patients described so far for either CYP2U1 or DDHD2 genes (1/150 mutated 
patient in either of the two cases) and close to 2 % for 
GBA2 (1/46 mutated patient). Although these ﬁgures may 
change depending upon population type, size and origin, 
the general indication is a low mutation frequency. On the 
other hand, these data underline once again the impressive 
genetic heterogeneity characterizing the group of compli-
cated spastic paraparesis with intellectual disability that 
still needs to be fully dissected. 
The GBA2 mutation shared by the three brothers, Web resources 
p.Gly683Arg, falls within the glucosylceramidase domain 
of the protein, the non-lysosomal b-glucosidase 2 enzyme, 1000genome database http://browser.1000genomes.org/ 
catalysing the conversion of glucosylceramide to free index.html. 
NCBI dbSNP http://www.ncbi.nlm.nih.gov/SNP/. 
SIFT and Provean http://sift.jcvi.org/. 
MutPred http://mutpred.mutdb.org/. 
evolutionary conservation of the affected residue, the SNAP https://rostlab.org/services/SNAP/. 
software’s predictions and the variant segregation within PhD-SNP http://snps.biofold.org/phd-snp/phd-snp.html. 
http://snps-and-go.biocomp.unibo.it/snps- 
http://www.pantherdb.org/tools/csnpScore 
SNPs&GO 
and-go/. 
Panther 
Form.jsp? 
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